Don’t Call it AI if it isn’t
July 31, 2025Tri-Specific Antibodies: Why the Next Generation of Biologics Matters for BD
July 31, 2025
Acute vs. Chronic: Why Pharma’s Focus is Long-Term (and What that Means for BD)
July 31, 2025
Liberi Group and Starodub B.V. Enter Consultancy Agreement
June 4, 2025
Liberi Group and C Cube Lab Announce Strategic Partnership to Accelerate Licensing & Business Development Services for Life Science Companies in South Korea
January 15, 2025
DEAL for Liberi Group Client| Theranexus and Exeltis (Insud Pharma) Announce Licensing Agreement to Commercialize Theranexus Tx01 for Two Rare Neurological Disorders
December 17, 2024
Scientific Advisor – Dr. Dave Roelen
October 19, 2022
DEAL for Liberi Group Client| GPCR Therapeutics and AdAlta Ltd!
October 13, 2022